10 patients with refractory SLE (cSLEDAI > 3, failure of 2+ immunosuppressants) treated with 1800mg daratumumab (+dexamethasone for injection reaction prevention) 1/week for 8 weeks.
Primary EP: reduction in dsDNA antibodies at week 12
Secondary EP: clinical effect, safety, immunology
2/
Lennard Ostendorf
